goal
vaccin
provid
last
immun
pathogen
vaccin
strategi
viral
infect
aim
gener
high
titr
highaffin
neutral
antibodi
bind
virion
prevent
product
viru
variat
virusencod
epitop
target
neutral
antibodi
complic
vaccin
strategi
exampl
three
polioviru
serotyp
distinct
neutral
epitop
polioviru
vaccin
high
efficaci
includ
three
strain
inactiv
attenu
influenza
virus
continu
evolv
strain
variat
due
mutat
neutral
epitop
encod
surfac
glycoprotein
variat
either
due
point
mutat
antigen
drift
driven
part
immun
select
attribut
complet
substitut
glycoprotein
gene
owe
reassort
influenza
virus
antigen
shift
new
influenza
viru
strain
frequent
emerg
requir
novel
influenza
vaccin
induc
appropri
neutral
antibodi
respons
influenza
pose
interest
addit
problem
immun
often
boost
product
nonprotect
antibodi
crossreact
previous
encount
strain
sometim
expens
induc
high
qualiti
protect
antibodi
respons
phenomenon
refer
origin
antigen
sin
wherebi
histori
respons
crossreact
antigen
bia
respons
toward
antigen
inhibit
respons
new
infect
dengu
virus
also
pose
problem
vaccin
design
effect
vaccin
million
human
infect
everi
year
four
dengu
viru
serotyp
defin
neutral
serotyp
otherwis
antigen
similar
nonneutr
antibodi
specif
one
dengu
serotyp
bind
second
dengu
serotyp
facilit
infect
cell
express
antibodi
fc
receptor
process
known
immun
enhanc
immun
enhanc
link
sever
case
dengu
haemorrhag
fever
dengu
shock
syndrom
immun
one
dengu
viru
serotyp
potenti
prime
individu
sever
infect
second
serotyp
viral
vaccin
current
licens
use
human
includ
inactiv
viru
prepar
hepat
influenza
japanes
enceph
polio
rabi
recombin
protein
hepat
b
papilloma
attenu
virus
passag
vitro
egg
reduc
virul
toward
human
adenoviru
measl
mump
polio
rubella
varicellazost
yellow
fever
modifi
vaccinia
viru
vv
vaccin
smallpox
although
studi
use
passiv
transfer
serum
clearli
shown
antibodi
alon
provid
protect
immun
virus
gener
thought
vaccin
induc
tcell
respons
addit
bcell
respons
produc
better
longer
last
protect
immun
inactiv
recombin
vaccin
induc
respons
helper
cell
whose
tcell
receptor
tcr
recogn
viral
peptid
captur
antigenpres
cell
process
present
class
ii
major
histocompat
complex
mhc
molecul
attenu
vaccin
better
inactiv
recombin
vaccin
stimul
good
tcell
respons
cell
infect
live
replic
viru
load
viral
peptid
epitop
onto
class
mhc
molecul
epitopecharg
mhc
molecul
target
cell
mani
paper
indic
cell
effect
clear
acut
viral
infect
control
lowlevel
persist
infect
caus
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herp
simplex
virus
hsv
cell
thought
especi
import
control
hepat
c
viru
hcv
infect
target
experiment
vaccin
studi
three
gener
conclus
reach
regard
tcell
respons
viral
infect
first
although
mani
viral
peptid
process
present
mhc
molecul
tcell
respons
mostli
direct
rel
small
number
discret
immunodomin
epitop
caus
immunodomin
complet
understood
requir
abil
cell
enzymat
digest
protein
particular
peptid
requir
peptid
appropri
aminoacid
sequenc
bind
good
affin
antigenpres
groov
mhc
amount
protein
synthes
synthes
infect
cycl
also
import
factor
mani
domin
epitop
deriv
protein
express
earli
infect
cellular
antigenpres
system
shut
event
occur
mani
viral
infect
great
import
avail
repertoir
cell
recogn
studi
indic
one
naiv
cell
recogn
specif
epitop
though
averag
number
like
vari
immunodomin
pattern
antigen
epitop
alter
host
previous
infect
pathogen
tcell
crossreact
tcell
recognit
complex
quit
degener
estim
singl
tcr
recogn
might
partli
due
abil
tcr
adjust
conform
bind
part
peptid
present
tcell
memori
pool
contain
cell
crossreact
epitop
newli
encount
viru
cell
could
prolifer
domin
subsequ
respons
human
difficult
determin
whether
epitop
intrins
immunodomin
whether
immunodomin
attribut
crossreact
previous
encount
pathogen
second
broadbas
tcell
respons
direct
sever
epitop
note
exampl
individu
tcell
respons
direct
mainli
singl
epitop
develop
fullblown
aid
rapidli
individu
tcell
respons
direct
sever
one
advantag
broadbas
immun
respons
viru
less
like
accumul
mutat
enabl
escap
immun
respons
studi
hcv
chimpanze
lymphocyt
choriomening
viru
lcmv
mice
correl
narrow
tcell
repertoir
gener
escap
second
advantag
broadbas
tcell
respons
condit
high
viral
load
might
difficult
viru
exhaust
immun
respons
sever
epitop
exhaust
respons
singl
repeat
stimul
cell
stun
render
dysfunct
anerg
drive
apoptosi
process
known
activationinduc
cell
impair
elimin
specif
cell
known
clonal
exhaust
studi
persist
lcmv
infect
mice
reveal
differ
degre
tcell
exhaust
vari
third
delic
balanc
abil
cell
provid
protect
immun
clear
infect
propens
mediat
damag
immunopatholog
balanc
protect
immun
immunopatholog
might
consequ
number
respond
cell
compar
efficaci
clear
viru
dna
immun
mice
lcmv
nucleoprotein
gene
encod
potent
tcell
epitop
result
rapid
immunopatholog
mice
subsequ
infect
intracerebr
lcmv
contrast
dna
immun
glycoprotein
gene
encod
neutral
antibodi
epitop
well
tcell
epitop
result
protect
past
year
concert
effort
made
identifi
immunodomin
tcell
epitop
sever
human
virus
incorpor
epitop
vaccin
specif
sequenc
code
epitop
cytokin
enhanc
factor
incorpor
viral
vector
dna
vaccin
approach
offer
promis
tumour
immunotherapi
design
vaccin
incorpor
immunogen
epitop
present
human
tumour
opinion
howev
question
whether
design
vaccin
small
number
epitop
good
strategi
viru
infect
mani
potenti
epitop
present
variou
mhc
molecul
attend
possibl
viral
escap
variant
differ
crossreact
particular
question
viral
epitop
sometim
pathogen
induc
tcell
respons
caus
immunopatholog
rather
protect
immun
altern
induc
poorli
protect
tcell
respons
inhibit
induct
respons
protect
epitop
cell
heterolog
immun
heterolog
immun
term
use
describ
partial
immun
alter
immunopatholog
occur
respons
pathogen
host
previous
infect
immun
unrel
pathogen
case
heterolog
immun
attribut
cell
crossreact
pathogen
tcell
crossreact
document
two
epitop
viral
epitop
differ
protein
importantli
epitop
protein
differ
mani
exampl
tcell
crossreact
among
virus
document
crossreact
perhap
unsurprisingli
occur
genet
relat
virus
within
viru
group
flavivirus
dengu
orthomyxovirus
influenza
surprisingli
tcell
crossreact
found
unrel
virus
exampl
cell
specif
distinct
influenza
viru
antigen
crossreact
antigen
cell
specif
arenavirus
lcmv
pichind
viru
pv
crossreact
antigen
poxviru
human
cell
specif
coronaviru
epitop
crossreact
papillomaviru
crossreact
might
due
high
level
aminoacid
sequenc
similar
epitop
although
alway
case
crossreact
occur
immunodomin
influenza
viru
epitop
major
ebvspecif
epitop
epitop
share
three
nine
amino
acid
host
immun
one
viru
infect
anoth
viru
encod
crossreact
epitop
shift
immunodomin
crossreact
memorytcel
popul
might
present
much
higher
frequenc
antigenspecif
naiv
cell
could
therefor
domin
respons
narrow
tcr
repertoir
extens
analysi
cell
repertoir
produc
respons
crossreact
class
mhc
kbrestrict
epitop
lcmv
pv
carri
two
epitop
share
six
eight
amino
acid
highli
crossreact
effector
tcr
clonal
analys
show
mice
infect
either
lcmv
pv
gener
broadbas
tcell
respons
everi
clone
sequenc
least
distinct
clonotyp
homolog
challeng
lcmvimmun
mice
lcmv
slightli
skew
respons
toward
predict
clonotyp
typic
aminoacid
pattern
motif
antigenbind
complementaritydetermin
region
tcr
howev
follow
heterolog
viral
challeng
dramat
narrow
tcell
repertoir
observ
probabl
subset
memori
cell
react
crossreact
peptid
suffici
affin
induc
prolifer
thu
tcell
respons
skew
toward
normal
subdomin
epitop
fig
normal
divers
tcr
usag
reduc
narrow
oligoclon
respons
predict
pvimmun
mice
infect
dose
lcmv
suffici
caus
persist
infect
gener
epitop
escap
mutant
lcmv
presenc
narrow
tcell
one
caveat
although
repertoir
narrow
might
expect
occur
case
alway
occur
repertoir
narrow
start
case
heterolog
immun
might
actual
broaden
respons
recruit
cell
would
normal
domin
tcr
repertoir
specif
epitop
divers
first
place
unclear
although
one
report
correl
divers
complex
aminoacid
epitop
side
chain
present
impact
tcr
privat
specif
genet
ident
individu
monozygot
twin
genet
differ
immun
system
bcell
repertoir
gener
independ
random
dna
recombin
naiv
tcell
repertoir
million
cell
present
low
frequenc
immun
respons
viral
infect
similar
genet
ident
naiv
mice
despit
differ
tcr
shown
fig
genet
ident
individu
mount
quantit
similar
acut
respons
use
differ
tcell
repertoir
howev
immun
repertoir
alter
deposit
highli
expand
clone
memori
cell
vari
sequenc
individu
impact
privat
tcr
repertoir
might
subsequ
observ
follow
infect
heterolog
pathogen
exampl
sequenti
infect
studi
use
lcmv
pv
discuss
previous
reveal
dramat
differ
magnitud
crossreact
respons
crossreact
epitopespecif
tcr
usag
variat
crossreact
respons
reflect
privat
specif
immun
repertoir
individu
immun
mice
transfer
splenocyt
one
immun
donor
three
naiv
recipi
mice
result
quantit
qualit
similar
tcell
respons
challeng
heterolog
viru
studi
indic
privat
specif
tcr
repertoir
uniqu
individu
might
central
role
immun
respons
virus
infect
crossreact
respons
heterolog
immun
present
also
impli
individu
might
experi
differ
type
patholog
heterolog
immun
factor
alter
immunopatholog
pattern
crossreact
experiment
model
suggest
chang
tcell
hierarchi
accompani
chang
viral
load
alter
chang
patholog
consequ
heterolog
immun
studi
challeng
mice
immun
lcmv
vv
vv
grow
higher
titr
naiv
mice
compar
lcmvimmun
mice
adopt
transfer
studi
implic
lcmvspecif
memori
cell
protect
despit
chang
protect
immun
consider
differ
immunopatholog
naiv
mice
intranas
infect
vv
develop
sever
airwayobstruct
oedema
lung
wherea
lcmvimmun
mice
infect
vv
littl
oedema
instead
larg
defin
cellular
infiltr
bronchusassoci
lymphoid
tissu
balt
contain
lcmvspecif
addit
mice
present
bronchiol
obliteran
patholog
unknown
aetiolog
human
occur
infect
lung
transplant
wherea
naiv
mice
infect
intraperiton
vv
littl
patholog
viscer
fat
periton
caviti
lcmvimmun
mice
challeng
vv
experi
sever
fatti
necrosi
pannicul
associ
infiltr
fat
lcmvspecif
resembl
patholog
erythema
nodosum
human
diseas
unknown
origin
sometim
occur
vaccin
viral
infect
tcell
crossreact
lcmv
vv
complex
involv
sever
epitop
epitop
specif
lcmvspecif
cell
prolifer
respons
vv
infect
vari
among
lcmvimmun
variat
tcell
crossreact
individu
also
function
privat
specif
tcell
repertoir
rather
random
event
adopt
transfer
splenocyt
lcmvimmun
donor
mice
three
naiv
recipi
result
similar
specif
lcmvspecif
recal
respons
follow
vv
challeng
indic
even
though
two
individu
similar
mhc
composit
experi
infect
two
virus
individu
necessarili
gener
strong
crossreact
tcell
respons
epitop
shown
fig
might
reflect
variat
result
immunopatholog
suffer
viral
load
heterolog
immun
studi
heterolog
immun
pathogen
mice
shown
reduc
level
replic
challeng
viru
quantifi
viral
plaqu
assay
earli
day
postinfect
associ
inhibit
activ
preexist
memori
cell
synthesi
high
level
interferon
ifn
pathogen
combin
increas
replic
challeng
pathogen
much
like
observ
antibodymedi
immun
enhanc
dengu
viru
exampl
although
prior
infect
influenza
viru
might
render
mous
resist
subsequ
vv
infect
increas
suscept
mous
infect
lcmv
murin
mechan
underli
phenomenon
elucid
might
relat
alter
tcell
respons
owe
heterolog
immun
less
effici
control
viral
titr
compar
newli
gener
cell
naiv
repertoir
human
diseas
heterotyp
immun
influenza
viru
term
heterolog
immun
current
use
describ
potenti
impact
tcelldepend
crossreact
immun
unrel
term
heterotyp
immun
long
use
describ
tcell
respons
preserv
determin
differ
variant
influenza
viru
system
conceptu
origin
antigen
sin
antibodi
cell
crossreact
differ
influenza
strain
domin
immun
viral
strain
mutat
tcell
epitop
narrow
tcell
repertoir
noteworthi
influenza
virus
infect
human
past
year
express
conserv
immunodomin
individu
infect
seri
influenza
strain
lifetim
tcr
repertoir
specif
epitop
evolv
divers
use
sever
famili
virtual
exclus
respons
use
discret
aminoacid
motif
region
whether
respons
help
control
influenza
viral
infect
unclear
seem
unlik
particularli
benefici
immun
individu
remain
suscept
infect
crossreact
influenza
viru
strain
crossreact
influenza
viru
ebv
mani
viral
diseas
result
sever
symptom
teenag
young
adult
young
diseas
includ
chicken
pox
measl
mump
polio
perhap
characterist
infecti
mononucleosi
differ
clinic
subclin
case
infecti
mononucleosi
seem
relat
magnitud
tcell
respons
rather
viru
propos
diseas
sever
patholog
older
age
group
might
involv
activ
crossreact
memori
cell
gener
respons
previous
encount
viru
immun
respons
may
robust
owe
gener
high
frequenc
memori
cell
may
suffici
affin
broadli
base
enough
rapidli
clear
pathogen
consist
hypothesi
cell
crossreact
influenza
epitop
main
immunodomin
epitop
ebv
present
high
frequenc
infecti
wide
variat
sever
infecti
mononucleosi
crossreact
found
patient
perhap
reflect
privat
specif
patient
immun
tcell
repertoir
although
plausibl
ebv
infect
well
infect
potenti
crossreact
virus
serv
modifi
influenzaspecif
tcell
repertoir
individu
age
possibl
studi
crossreact
influenza
viru
hcv
one
viral
diseas
present
extrem
differ
symptom
individu
hepat
c
hcv
caus
either
clinic
subclin
infect
either
clear
host
caus
lifelong
persist
infect
reason
variat
unknown
tcell
crossreact
howev
found
major
immunodomin
epitop
hcv
epitop
influenza
studi
carri
breadth
tcell
respons
librari
peptid
encompass
entir
hcv
genom
reveal
mani
acut
hcv
patient
gener
cell
recogn
wide
array
peptid
howev
two
patient
persist
sever
fulmin
hcv
found
narrow
tcell
respons
almost
exclus
direct
peptid
span
crossreact
influenza
viru
hcv
import
find
common
studi
carri
use
anim
model
link
sever
patholog
tcell
crossreact
human
patient
presum
previous
encount
influenza
viral
infect
privat
specif
probabl
dictat
domin
crossreact
tcell
respons
crossreact
differ
serotyp
dengu
viru
dengu
haemorrhag
fever
dengu
shock
syndrom
sever
diseas
occur
frequent
individu
immun
one
dengu
viru
serotyp
becom
infect
second
serotyp
four
serotyp
dengu
viru
syndrom
might
partli
due
presenc
immuneenhanc
antibodi
facilit
infect
cell
dengu
viru
crossreact
cell
might
also
involv
one
studi
show
tcell
respons
crossreact
epitop
dengu
viru
serotyp
infect
high
affin
previous
encount
dengu
viru
serotyp
rel
low
affin
newli
encount
dengu
viru
serotyp
ref
could
due
elicit
crossreact
memori
cell
domin
immun
respons
ineffici
clear
viru
dramat
variat
diseas
individu
infect
dengu
virus
could
inde
reflect
privat
specif
immun
respons
immun
deviat
differenti
cell
produc
cell
subtyp
character
distinct
pattern
cytokin
product
one
consequ
reactiv
memori
cell
synthesi
secret
larg
concentr
cytokin
program
reactiv
memori
cell
produc
type
cytokin
exampl
might
therefor
help
prime
new
respons
type
direct
wherea
reactiv
memori
cell
express
type
cytokin
exampl
might
drive
immun
respons
type
direct
classic
exampl
vaccin
gone
wrong
formalininactiv
respiratori
syncyti
viru
rsv
vaccin
administ
children
follow
exposur
children
wildtyp
rsv
sever
month
vaccin
mani
children
protect
infect
instead
develop
sever
infect
fatal
patient
present
clinic
unusu
lung
patholog
includ
eosinophilia
experiment
mous
model
rsv
reproduc
featur
diseas
balbc
mice
immun
rsv
g
protein
either
provid
adjuv
form
vv
recombin
vaccin
vvg
develop
sever
eosinophilia
tcell
respons
subsequ
challeng
rsv
contrast
respons
mount
nonvaccin
rsvchalleng
control
mice
easili
control
reason
sever
immun
deviat
result
combin
express
specif
class
ii
pathogen
epitop
encod
rsv
g
protein
rather
limit
repertoir
cell
express
howev
mice
infect
influenza
viru
prior
vvg
immun
develop
eosinophilia
subsequ
challeng
influenza
virusimmun
mice
challeng
vv
produc
much
higher
level
type
cytokin
vvchalleng
naiv
induc
heterolog
immun
influenza
vv
might
chang
type
cytokin
respons
type
cytokin
respons
follow
immun
vvg
molecular
mimicri
self
antigen
pathogen
epitop
autoimmun
term
pathogen
epitop
origin
coin
describ
epitop
target
autoimmun
reaction
experiment
autoimmun
enceph
eae
central
nervou
system
cn
diseas
anim
model
human
multipl
sclerosi
ms
mous
model
ms
pathogen
class
ii
mhcrestrict
epitop
encod
cn
protein
identifi
includ
epitop
deriv
myelin
basic
protein
mbp
myelin
proteolipid
protein
plp
myelin
oligodendrocyt
glycoprotein
protein
encephalitogen
peptid
deriv
protein
induc
eae
inject
adjuv
mice
pathogen
epitop
highli
specif
ntermin
aminoacid
sequenc
mbp
compris
pathogen
epitop
plj
strain
mous
mhc
ntermin
amino
acid
nonacetyl
peptid
use
eae
induc
develop
eae
highli
regul
process
epitop
administ
differ
immun
scheme
sometim
result
cell
anergi
toler
instead
autoimmun
tcell
respons
share
common
antivir
tcell
respons
compris
cell
react
sever
differ
epitop
inject
sjlj
mice
intact
plp
molecul
result
activ
cell
specif
codomin
epitop
immun
mice
either
epitop
induc
eae
mice
immun
subdomin
epitop
develop
eae
far
similarli
adopt
transfer
cell
mice
sensit
naiv
mice
result
slower
eae
develop
compar
induc
immun
interestingli
littl
reactiv
observ
mice
immun
intact
plp
therefor
refer
nondomin
cryptic
tcell
determin
although
autoimmun
often
initi
associ
pathogen
epitop
immun
respons
sometim
spread
epitop
encod
protein
exampl
immun
sjlj
mice
subsequ
gener
respons
led
concept
determin
case
activ
antigenpres
cell
within
inflammatori
milieu
engulf
myelin
degrad
present
myelin
epitop
cell
might
opposit
observ
sequenti
viral
infect
crossreact
could
drive
narrow
tcell
precipit
autoimmun
viral
infect
viral
self
epitop
crossreact
level
cell
b
cell
infect
anim
virus
encod
epitop
crossreact
self
antigen
infect
recombin
virus
encod
engin
selfepitop
result
activ
self
reactiv
cell
initi
autoimmun
diseas
epitop
express
protein
crossreact
corneal
antigen
murin
model
autoimmun
theiler
murin
encephalomyel
viru
tmev
infect
mice
induc
tmev
viral
protein
vp
crossreact
cell
produc
kill
uninfect
host
cell
transfer
cell
naiv
uninfect
mice
induc
cn
insert
bacteri
epitop
proteas
iv
haemophilu
influenza
tmev
increas
rate
tmevinduc
inflamm
incorpor
self
cn
protein
recombin
vv
also
prime
mice
autoimmun
studi
indic
autoimmun
might
induc
viral
infect
human
well
mice
predispos
human
autoimmun
diabet
glutam
acid
decarboxylas
target
autoantigen
diseas
studi
defin
tcell
crossreact
respons
epitop
sequenc
similar
autoantigen
cmvencod
mbpreactiv
cell
isol
ms
patient
react
variou
viral
bacteri
peptid
crossreact
viral
microbi
peptid
epitop
alway
share
aminoacid
similar
still
activ
mbpspecif
tcell
clone
recent
howev
cell
isol
ms
cerebrospin
fluid
shown
react
polyarginin
sequenc
similar
encod
cn
adrenerg
receptor
sever
virus
one
viru
encod
epitop
homolog
cn
adrenerg
receptor
ubiquit
torqu
teno
orphan
viru
small
dna
viru
replic
cn
associ
argininerich
domain
found
dnabind
protein
mani
virus
lead
possibl
exacerb
ms
could
relat
infect
differ
virus
occas
individu
develop
postinfecti
encephalomyel
follow
acut
measl
viru
inflammatori
respons
within
cn
mirror
eae
lewi
rat
post
infecti
encephalomyel
follow
infect
measl
viru
might
due
crossreact
immun
respons
measl
viru
cn
protein
yet
proven
autoimmun
heterolog
immun
experiment
model
system
studi
abil
viral
infect
break
toler
induc
autoimmun
includ
transgen
mice
express
viral
protein
self
lcmv
infect
induc
transient
enceph
limit
insul
transgen
mice
express
lcmv
nucleoprotein
brain
pancreat
islet
lcmv
infect
clear
heterolog
infect
either
pv
vv
induc
second
wave
cn
fig
model
might
mimic
viral
infectionassoci
exacerb
human
lcmv
infect
insul
model
note
pv
challeng
induc
pancreat
inflamm
diabet
associ
infiltr
prolifer
crossreact
cell
lcmv
infect
pv
infect
could
break
toler
pv
infect
lcmvimmun
mice
stimul
crossreact
cell
push
host
diabet
differ
experiment
model
ms
mice
immun
one
viru
encod
epitop
mimic
myelin
develop
cn
inflammatori
lesion
associ
demyelin
infect
differ
viru
mycobacterium
tuberculosi
adjuv
mice
infect
recombin
vv
encod
cn
protein
plp
clear
viru
two
week
vvimmun
mice
challeng
tuberculosi
adjuv
infect
murin
cmv
develop
cn
white
matter
one
explan
observ
first
viru
infect
prime
autoreact
cell
stimul
second
pathogen
possibl
owe
crossreact
howev
autoantigen
present
second
pathogen
might
stimul
diseas
bystand
activ
event
exampl
first
pathogen
expand
autoreact
cell
suffici
number
initi
cn
lesion
second
challeng
expand
crossreact
cell
therebi
caus
cn
lesion
fig
known
threshold
number
autoreact
cell
must
gener
sensit
regimen
provid
adopt
transfer
cell
autoimmun
diseas
occur
heterolog
immun
virus
provid
potenti
mechan
amplifi
autoimmun
respons
initi
first
viru
one
natur
situat
posit
occur
human
ms
sever
virus
encod
polyarginin
sequenc
recogn
cell
isol
pathogen
epitop
vaccin
design
clear
specif
virusencod
tcell
epitop
could
contribut
aberr
immunopatholog
viral
infect
might
achiev
stimul
immunodomin
lowaffin
oligoclon
respons
inhibit
broadbas
highaffin
respons
wellpres
epitop
deviat
protect
cytokin
respons
damag
cytokin
respons
elicit
respons
autoantigen
opinion
describ
lcmv
epitop
might
function
pathogen
epitop
model
heterolog
immun
influenza
epitop
could
pathogen
epitop
infecti
mononucleosi
patient
infect
crossreact
dengu
viru
epitop
might
contribut
lowaffin
tcell
respons
poor
clearanc
viru
dengu
haemorrhag
also
discuss
rsv
g
protein
epitop
might
produc
deviat
type
cytokineinduc
pathogen
immun
influenza
viru
epitop
could
contribut
narrowli
focus
immunodomin
tcell
respons
associ
fulmin
hcv
exampl
pathogen
epitop
seem
direct
immun
respons
away
best
suit
clear
viral
infect
minim
patholog
research
direct
defin
immunodomin
viral
epitop
order
includ
vaccin
design
strongli
focu
immun
respons
protect
epitop
improv
efficaci
immun
caution
emphasi
direct
vaccin
strategi
toward
small
number
immunodomin
epitop
broadbas
respons
use
divers
tcr
repertoir
direct
sever
epitop
might
provid
better
protect
immun
could
reduc
possibl
select
diseaseproduc
viru
escap
variant
suggest
clinic
experiment
addit
larg
variat
human
mhc
molecul
present
differ
peptid
epitop
virusencod
epitop
sequenc
sometim
occur
gener
escap
mutat
problemat
epitopebas
vaccin
design
perhap
equal
attent
direct
toward
elimin
pathogen
epitop
vaccin
empir
studi
link
aberr
human
immun
tcell
respons
immunopatholog
specif
epitop
elimin
vaccin
might
appropri
exampl
would
wise
develop
attenu
hcv
vaccin
contain
epitop
crossreact
influenza
viru
like
almost
recipi
hcv
vaccin
would
previous
infect
influenza
viru
probabl
vaccin
individu
would
develop
focus
oligoclon
respons
crossreact
epitop
might
promot
rather
inhibit
diseas
wise
includ
epitop
attenu
live
influenza
viru
vaccin
adult
tcell
respons
epitop
alreadi
might
inhibit
induct
broadbas
respons
influenza
epitop
shown
fig
would
make
sens
mutat
epitop
put
ebv
vaccin
might
crossreact
ubiquit
influenza
viru
epitop
advis
immun
individu
attenu
cmv
contain
epitop
stimul
crossreact
diabetesassoci
autoimmun
antigen
type
issu
long
time
consid
problemat
develop
dengu
viru
vaccin
given
correl
immuneenhanc
antibodi
dengu
haemorrhag
fever
argu
question
consid
new
vaccin
design
recogn
consider
come
sever
caveat
epitop
highli
conserv
influenza
epitop
might
difficult
delet
preserv
viabil
attenu
viru
importantli
mani
epitop
could
potenti
delet
might
contribut
protect
immun
respons
individu
riskbenefit
analysi
might
need
assess
protect
benefit
versu
could
rare
incid
damag
immun
patholog
heterolog
immun
often
benefici
crossreact
respons
augment
clearanc
challeng
inde
privat
specif
immun
respons
uniqu
individu
might
ensur
variabl
respons
patholog
experienc
vaccin
recipi
